Our client was a global biopharma company that is a leader in the rare disease space. Leaders at the company sought an understanding of the potential impact of loss of exclusivity (LOE) on sales of its drug for an ultra-rare orphan disease and recommendations for mitigating loss to a generic. As such, they asked Promidian to conduct a detailed assessment and develop recommendations for LOE strategy.
This project focused on LOE strategy in the US across payers, specialty pharmacy providers (SPPs), healthcare providers, and patients.
In developing a robust LOE assessment, we conducted primary research with a wide range of stakeholders, including individuals from payer and SPP organizations.
We also researched and developed in-depth analog case studies for companies facing LOE in various orphan diseases to identify key learnings for the client. Additionally, we developed detailed profiles and assessments of the expected generic competitors.
We then developed a detailed view of the likely market situation at LOE and implications for the brand with regard to pricing, sales, and risks to the brand with each stakeholder in the buying process.
Finally, we identified potential strategies for each stakeholder in the buying process, including physicians, patients, payers, and specialty pharmacy.
Do you have a robust strategy to maximize the value of your in-line brands? Promidian can help. Contact us today.